In addition, a double-blind RCT showed that the administration of ebastine, which is an antagonist of the histamine receptor H1 and inhibits the TRPV1 pathway, reduced visceral sensitivity and abdominal pain in patients with IBS [40]. Here, TRPV1 is linked to irritable bowel syndrome.